Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine

Siegel, 2018, Cancer statistics, 2018, CA Cancer J Clin, 68, 7, 10.3322/caac.21442 Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 Gillen, 2010, Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages, PLoS Med, 7, e1000267, 10.1371/journal.pmed.1000267 Oettle, 2013, Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial, JAMA, 310, 1473, 10.1001/jama.2013.279201 Groot, 2018, Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma, J Surg Res, 221, 152, 10.1016/j.jss.2017.08.023 Strobel, 2019, Optimizing the outcomes of pancreatic cancer surgery, Nat Rev Clin Oncol, 16, 11, 10.1038/s41571-018-0112-1 Conroy, 2018, FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer, N Engl J Med, 379, 2395, 10.1056/NEJMoa1809775 Liu, 2018, Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer, BMC Gastroenterol, 18, 168, 10.1186/s12876-018-0891-y Versteijne, 2020, Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial, J Clin Oncol, 38, 1763, 10.1200/JCO.19.02274 Mayo, 2012, Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy, J Am Coll Surg, 214, 33, 10.1016/j.jamcollsurg.2011.09.022 Merkow, 2014, Post-operative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer, Ann Surg, 260, 372, 10.1097/SLA.0000000000000378 Valle, 2014, Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study, J Clin Oncol, 32, 504, 10.1200/JCO.2013.50.7657 Jang, 2018, Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial, Ann Surg, 268, 215, 10.1097/SLA.0000000000002705 Maggino, 2019, Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma, JAMA Surg, 154, 932, 10.1001/jamasurg.2019.2277 Lee, 2019, Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: a systematic review and meta-analysis, Sci Rep, 9, 15662, 10.1038/s41598-019-52167-9 Bradley, 2019, Upfront Surgery versus neoadjuvant therapy for resectable pancreatic cancer: systematic review and bayesian network meta-analysis, Sci Rep, 9, 4354, 10.1038/s41598-019-40951-6 Chawla, 2019, Neoadjuvant therapy for resectable pancreatic cancer: an evolving paradigm shift, Front Oncol, 9, 1085, 10.3389/fonc.2019.01085 Mokdad, 2017, Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis, J Clin Oncol, 35, 515, 10.1200/JCO.2016.68.5081 Roland, 2015, Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer, Ann Surg Oncol, 22, 1168, 10.1245/s10434-014-4192-6 Laurence, 2011, A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer, J Gastrointest Surg, 15, 2059, 10.1007/s11605-011-1659-7 Ye, 2020, Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis, HPB (Oxford), 22, 821, 10.1016/j.hpb.2020.01.001 Janssen, 2020, Neoadjuvant treatment in patients with resectable and borderline resectable pancreatic cancer, Front Oncol, 10, 41, 10.3389/fonc.2020.00041 Kulkarni, 2020, White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: part I, AJCC staging system, NCCN guidelines, and borderline resectable disease, Abdom Radiol (NY), 45, 716, 10.1007/s00261-019-02289-5 Oba, 2020, Neoadjuvant treatment in pancreatic cancer, Front Oncol, 10, 245, 10.3389/fonc.2020.00245 Ferrone, 2015, Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer, Ann Surg, 261, 12, 10.1097/SLA.0000000000000867 Varadhachary, 2006, Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy, Ann Surg Oncol, 13, 1035, 10.1245/ASO.2006.08.011 Dixon, 2010, AHPBA/SSO/SSAT sponsored consensus conference on multidisciplinary treatment of hepatocellular carcinoma, HPB (Oxford), 12, 287, 10.1111/j.1477-2574.2010.00184.x Katz, 2013, Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design, Ann Surg Oncol, 20, 2787, 10.1245/s10434-013-2886-9 Bockhorn, 2014, Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS), Surgery, 155, 977, 10.1016/j.surg.2014.02.001 Isaji, 2018, International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017, Pancreatology, 18, 2, 10.1016/j.pan.2017.11.011 Tempero, 2019, NCCN guidelines updates: pancreatic cancer, J Natl Compr Canc Netw, 17, 603 Tang, 2016, Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: a systematic review and meta-analysis of response and resection percentages, Pancreatology, 16, 28, 10.1016/j.pan.2015.11.007 Janssen, 2019, Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis, J Natl Cancer Inst, 111, 782, 10.1093/jnci/djz073 Versteijne, 2020, Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial, J Clin Oncol, 38, 1763, 10.1200/JCO.19.02274 Xu, 2014, Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis, J Cancer Res Clin Oncol, 140, 549, 10.1007/s00432-013-1572-4 Suker, 2016, FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis, Lancet Oncol, 17, 801, 10.1016/S1470-2045(16)00172-8 Kleeff, 2019, Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer?, EClinicalMedicine, 17, 100222, 10.1016/j.eclinm.2019.11.015 Jung, 2019, Stereotactic body radiation therapy for locally advanced pancreatic cancer, PLoS One, 14, e0214970, 10.1371/journal.pone.0214970 Tempero, 2019, Pancreatic adenocarcinoma, version 1.2019, J Natl Compr Canc Netw, 17, 202, 10.6004/jnccn.2019.0014 Pentheroudakis, 2019, Recent eupdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer, Ann Oncol, 30, 1395, 10.1093/annonc/mdz180 Khorana, 2019, Potentially curable pancreatic adenocarcinoma: ASCO Clinical Practice Guideline update, J Clin Oncol, 37, 2082, 10.1200/JCO.19.00946 Gulhati, 2019, First-line gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma, Ann Surg Oncol, 26, 619, 10.1245/s10434-018-6807-9 Paiella, 2019, Ablation treatments in unresectable pancreatic cancer, Minerva Chir, 74, 263, 10.23736/S0026-4733.18.07881-1 Ducreux, 2015, Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26, v56, 10.1093/annonc/mdv295 Pan, 2019, Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis, World J Surg Oncol, 18, 1, 10.1186/s12957-019-1767-5 Reni, 2018, Safety and efficacy of preoperative or post-operative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial, Lancet Gastroenterol Hepatol, 3, 413, 10.1016/S2468-1253(18)30081-5 Ghaneh, 2020, J Clin Oncol, 38, 4505, 10.1200/JCO.2020.38.15_suppl.4505 Sohal, 2020, SWOG S1505: results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA), J Clin Oncol, 38, 4504, 10.1200/JCO.2020.38.15_suppl.4504 Gilbert, 2017, Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification, Ann Oncol, 28, 2067, 10.1093/annonc/mdx180 Heinrich, 2019, Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study, BMC Cancer, 19, 675, 10.1186/s12885-019-5889-5 Dreyer, 2017, Pancreatic cancer genomes: implications for clinical management and therapeutic development, Clin Cancer Res, 23, 1638, 10.1158/1078-0432.CCR-16-2411 Biankin, 2012, Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes, Nature, 491, 399, 10.1038/nature11547 Waddell, 2015, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, 518, 495, 10.1038/nature14169 Bailey, 2016, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531, 47, 10.1038/nature16965 Pishvaian, 2019, Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the know your tumour program, JCO Precision Oncology, 3, 1, 10.1200/PO.19.00115 Aguirre, 2018, Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine, Cancer Discov, 8, 1096, 10.1158/2159-8290.CD-18-0275 Aung, 2018, Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial, Clin Cancer Res, 24, 1344, 10.1158/1078-0432.CCR-17-2994 Park, 2020, Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection, Clin Cancer Res, 26, 3239, 10.1158/1078-0432.CCR-20-0418 Golan, 2018, Phase II study of olaparib for BRCAness phenotype in pancreatic cancer, J Clin Oncol, 36, 297, 10.1200/JCO.2018.36.4_suppl.297 Zhu, 2020, PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications, Mol Cancer, 19, 49, 10.1186/s12943-020-01167-9 Golan, 2019, Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, N Engl J Med, 381, 317, 10.1056/NEJMoa1903387 Sahin, 2017, Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?, Ann Oncol, 28, 2950, 10.1093/annonc/mdx503 Martens, 2019, Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications, Ann Oncol, 30, 1428, 10.1093/annonc/mdz181 Collisson, 2019, Molecular subtypes of pancreatic cancer, Nat Rev Gastroenterol Hepatol, 16, 207, 10.1038/s41575-019-0109-y Collisson, 2011, Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat Med, 17, 500, 10.1038/nm.2344 Nagtegaal, 2020, The 2019 WHO classification of tumours of the digestive system, Histopathology, 76, 182, 10.1111/his.13975 Moffitt, 2015, Virtual microdissection identifies distinct tumour- and stroma-specific subtypes of pancreatic ductal adenocarcinoma, Nat Genet, 47, 1168, 10.1038/ng.3398 Hoadley, 2014, Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin, Cell, 158, 929, 10.1016/j.cell.2014.06.049 Martinelli, 2017, GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer, Gut, 66, 1665, 10.1136/gutjnl-2015-311256 O'Kane, 2020, GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer, Clin Cancer Res, 26, 4901, 10.1158/1078-0432.CCR-19-3724 Martinelli, 2017, GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer, Gut, 66, 1665, 10.1136/gutjnl-2015-311256 Dreyer, 2020, Precision oncology in surgery: patient selection for operable pancreatic cancer, Ann Surg, 272, 366, 10.1097/SLA.0000000000003143 Dreyer, 2020, Pancreatic cancer: from genome discovery to PRECISION-Panc, Clin Oncol (R Coll Radiol), 32, 5, 10.1016/j.clon.2019.08.007 Murphy, 2018, Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial, JAMA Oncol, 4, 963, 10.1001/jamaoncol.2018.0329 He, 2018, Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer?, Ann Surg, 268, 1, 10.1097/SLA.0000000000002672 Gemenetzis, 2019, Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection, Ann Surg, 270, 340, 10.1097/SLA.0000000000002753 Motoi, 2019, Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05), Jpn J Clin Oncol, 49, 190, 10.1093/jjco/hyy190 Zhao, 2012, Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis, Ann Diagn Pathol, 16, 29, 10.1016/j.anndiagpath.2011.08.005 Khattab, 2019, Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma, J Gastrointest Oncol, 10, 918, 10.21037/jgo.2019.07.02 Townend, 2018, Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data, ANZ J Surg, 88, E167, 10.1111/ans.13897 Golan, 2020, Increased rate of complete pathologic response after neoadjuvant FOLFIRINOX for BRCA mutation carriers with borderline resectable pancreatic cancer, Ann Surg Oncol, 27, 3963, 10.1245/s10434-020-08469-8 He, 2018, Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer?, Ann Surg, 268, 1, 10.1097/SLA.0000000000002672 Patil, 2020, EZH2 regulates pancreatic cancer subtype identity and tumour progression via transcriptional repression of GATA6, Cancer Res, 80, 4620, 10.1158/0008-5472.CAN-20-0672 Chang, 2014, Mining the genomes of exceptional responders, Nat Rev Cancer, 14, 291, 10.1038/nrc3723 Rombouts, 2016, Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer, Ann Surg Oncol, 23, 4352, 10.1245/s10434-016-5373-2 Park, 2019, Homologous recombination deficiency (HRD): a biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC), J Clin Oncol, 37, 4132, 10.1200/JCO.2019.37.15_suppl.4132 Torgeson, 2017, Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer, Cancer, 123, 3816, 10.1002/cncr.30780 Nevala-Plagemann, 2020, From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer, Nat Rev Clin Oncol, 17, 108, 10.1038/s41571-019-0281-6 Berger, 2018, The emerging clinical relevance of genomics in cancer medicine, Nat Rev Clin Oncol, 15, 353, 10.1038/s41571-018-0002-6 Ersek, 2018, Implementing precision medicine programs and clinical trials in the community-based oncology practice: barriers and best practices, Am Soc Clin Oncol Educ Book, 38, 188, 10.1200/EDBK_200633 Kitano, 2019, Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer, J Gastroenterol, 54, 19, 10.1007/s00535-018-1519-2 Baek, 2015, Diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology of pancreatic lesions, J Pathol Transl Med, 49, 52, 10.4132/jptm.2014.10.26 Cros, 2018, Tumour heterogeneity in pancreatic adenocarcinoma, Pathobiology, 85, 64, 10.1159/000477773 Vietsch, 2018, Reprint of: circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer, Cancer Genet, 228-229, 131, 10.1016/j.cancergen.2018.11.001 Ahola, 2020, Centralization of pancreatic surgery improves results: review, Scand J Surg, 109, 4, 10.1177/1457496919900411 Balzano, 2020, Modelling centralization of pancreatic surgery in a nationwide analysis, Br J Surg, 107, 1510, 10.1002/bjs.11716 Dreyer, 2020, PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer, Clin Oncol (R Coll Radiol), 32, 1, 10.1016/j.clon.2019.07.011 Dreyer, 2019, Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling, Chin Clin Oncol, 8, 16, 10.21037/cco.2019.04.06 Lowery, 2017, Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype, Clin Cancer Res, 23, 6094, 10.1158/1078-0432.CCR-17-0899 Chantrill, 2015, Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial, Clin Cancer Res, 21, 2029, 10.1158/1078-0432.CCR-15-0426 Lee, 2019, Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations, J Clin Oncol, 37, e15753, 10.1200/JCO.2019.37.15_suppl.e15753 Marchegiani, 2018, Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma?, HPB (Oxford), 20, 411, 10.1016/j.hpb.2017.10.017 Kirkegard, 2019, Waiting time to surgery and pancreatic cancer survival: a nationwide population-based cohort study, Eur J Surg Oncol, 45, 1901, 10.1016/j.ejso.2019.05.029 Mirkin, 2018, Time to surgery: a misguided quality metric in early stage pancreatic cancer, J Gastrointest Surg, 22, 1365, 10.1007/s11605-018-3730-0 Yu, 2019, Retrospective survival analysis of patients with resected pancreatic ductal adenocarcinoma and a germline BRCA or PALB2 mutation, JCO Precision Oncology, 3, 1, 10.1200/PO.18.00271 Dreyer, 2021, Targeting DNA damage response and replication stress in pancreatic cancer, Gastroenterology, 160, 362, 10.1053/j.gastro.2020.09.043 Kocher, 2020, Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer, Nat Commun, 11, 4841, 10.1038/s41467-020-18636-w Tuli, 2014, Radiosensitization of pancreatic cancer cells in vitro and in vivo through poly (ADP-ribose) polymerase inhibition with ABT-888, Transl Oncol, 7, 439, 10.1016/j.tranon.2014.04.003 Tuli, 2019, A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer, EBioMedicine, 40, 375, 10.1016/j.ebiom.2018.12.060